Literature DB >> 22802329

Significant hypotension following buccal midazolam administration.

Maria Kensche1, Josemir W Sander, Sanjay M Sisodiya.   

Abstract

Buccal midazolam is a rescue medication to reduce the duration of or stop an epileptic seizure, and is used to prevent status epilepticus. It is available in various forms, including a buccal preparation with a strength of 10 mg/1 ml. Midazolam is a licensed medication, but the buccal formulation is currently used off-licence. The prescriber takes ultimate responsibility for its use in this way. Administered by a trained person, it is receiving widespread acceptance as an alternative and effective treatment to rectally-administered diazepam in the community. The commonest side effects of midazolam are drowsiness and somnolence, although respiratory depression and paradoxical reactions, for example, agitation, restlessness and disorientation, may also occur. Hypotension is said to be a rare side effect, but with no reported cases in people administered buccal midazolam. The authors report a case of significant hypotension associated with administration of buccal midazolam for seizure management.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22802329      PMCID: PMC3029668          DOI: 10.1136/bcr.09.2010.3371

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  Nasal/buccal midazolam use in the community.

Authors:  M T Wilson; S Macleod; M E O'Regan
Journal:  Arch Dis Child       Date:  2004-01       Impact factor: 3.791

Review 2.  Status epilepticus: an evidence based guide.

Authors:  Matthew Walker
Journal:  BMJ       Date:  2005-09-24

3.  Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial.

Authors:  John McIntyre; Sue Robertson; Elizabeth Norris; Richard Appleton; William P Whitehouse; Barbara Phillips; Tim Martland; Kathleen Berry; Jacqueline Collier; Stephanie Smith; Imti Choonara
Journal:  Lancet       Date:  2005 Jul 16-22       Impact factor: 79.321

4.  A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy.

Authors:  D M Bell; G Richards; S Dhillon; J R Oxley; J Cromarty; J W Sander; P N Patsalos
Journal:  Epilepsy Res       Date:  1991 Nov-Dec       Impact factor: 3.045

  4 in total
  1 in total

1.  Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability.

Authors:  Mark Anderson
Journal:  Patient Prefer Adherence       Date:  2013-01-10       Impact factor: 2.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.